By Colin Kellaher

 

Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Friday said it is seeking U.S. Food and Drug Administration approval of its arthritis drug Simponi Aria in a pair of juvenile indications.

The drug maker said it filed supplemental biologics license applications for the drug for the treatment of polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in patients two years of age and older in combination with methotrexate.

Janssen said Simponi Aria, if approved for the indications, would be the first anti-tumor necrosis factor-alpha biologic agent administered by intravenous infusion available for such juvenile patients.

The FDA previously approved Simponi Aria for adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

April 24, 2020 10:11 ET (14:11 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Johnson and Johnson Charts.